

Myers (\$BMY)--which splits global revenues evenly with Pfizer (\$PFE)-reported late last month, it hauled in \$171 million in Eliquis revenue for the second quarter. That's more than 13 times

the \$12 million it posted in the same period last year, and more than 50% above what it generated last quarter.

That turnaround is no accident. BMS and Pfizer have devoted "increased resources" to DTC advertising in the U.S. and expanded their sales forces and peer-to-peer medical education activities in all countries, Bristol CEO Lamberto Andreotti told investors on a conference call.

TOOLS









[Webinar] Special Considerations for Managing Immuno-oncology Studies - A New Paradigm DATE: WEDNESDAY, MARCH 9 I 11AM ET / 8AM PT

Immuno-Oncology Webinar; We are in a new era for researching cancer treatments. Join Medpace medical and operations experts as they discuss the unique considerations for managing immuno-oncology studies as well as insights into best practices. Reserve Your Spot Today!

Sign up for our FREE newsletter for more news like this sent to your inbox!

Eliquis also racked up a new indication in March, scoring a nod for use after ortho surgery. And with the DVT/PE recommendations it has snagged in the U.S. and-more recently--Europe, more label expansions could soon be on the way.

Strengthening access to Eliquis hasn't hurt, either. "We have very strong preferred access to the tune of about 60% on the commercial side and 80% on the Medicare side. And this obviously is a development that will continue to generate growth going forward," Bristol COO Giovanni Caforio told investors.

As a result of all these efforts, Eliquis' new-to-brand share among cardiologists--Bristol's primary area of focus--has grown nearly 8 share points since the start of

# JOIN 24,000+ INSIDERS SIGN UP FOR OUR NEWSLETTER

FiercePharmaMarketing is the leading source of pharma marketing news with a special focus on consumer advertising, DTC trends, new drug launches, and more. Join your fellow pharma FiercePharmaMarketing via email. Sign up today!

SIGN ME UP

SIGN ME UP

Q

# **Tracking Trends in** Consumer Health Dose

Formulation



## POPULAR STORIES

MOST SHARED

# THE LIBRARY: WEBINAR

Physician Prescribing Trends & Opportunities for Health System-Pharma Collaboration



| WEDNESDAY, MARCH 16 | 11AM ET / 8AM PT | PRESENTED BY: ATHENAHEAI TH

athenahealth conducted a study to learn how health systems and new reimbursement models are impacting prescribing behavior. We'll discuss our findings, including opportunities for pharma marketers, with a health system leader during this webinar. Reserve Your Spot Today!

MORE ITEMS



the year, BMS CFO Charlie Bancroft said, and Caforio added that new-to-brand prescriptions have also grown significantly in primary care.

So does that mean Eliquis is finally on the road to achieving the \$3-billion-a-year sales analysts forecast before its launch? Not necessarily. The med still has a couple formidable opponents to contend with in Boehringer Ingelheim's Pradaxa and market-leading Xarelto from Johnson & Johnson (\$JNJ) and Bayer, both blockbusters in their own right.

"It's too early to declare victory, but—interesting trend shift," ISI Group analyst Mark Schoenebaum said in an investor video.

- see the BMS call transcript

Special Reports: Blockbuster buzz: 15 Top Therapies - Eliquis | Top 10 DTC pharma advertisers

### Related Articles:

Eliquis scores DVT/PE recommendation in Europe

Bristol-Myers' Eliquis gets new FDA nod for use after ortho surgery

Eliquis earns best safety score in its class in analysis of FDA adverse event reports


Bristol-Myers is counting on DTC to keep driving Eliquis growth

Which new drugs promise to shake up markets the most?

EP Vantage: Eliquis projected sales off 60% for 2014

Pfizer, Bristol-Myers tout new VTE data on Eliquis, aiming for new use

EMAIL ADDRESS SIGN ME UP



# LATEST COMMENTARY =

Pharma marketers steer through changing tides

What caught our readers' fancy this year? Here's your top 10 FiercePharmaMarketing capsule

Merck KGaA exits 'sea of sameness' with futuristic rebrand

For sale: Orange paint. It might just become your brand's signature

FiercePharmaMarketing will now publish every Monday and Wednesday

### **EVENTS**

Brand New Modular Bioprocessing Facility From Novartis February 17, 2016 — Charleston, SC

MORE EVENTS





